Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Open access
Tariot, Pierre N., Braeckman, Rene, Oh, Charles · 2022 · Journal of Alzheimer's Disease

Abstract

Background: Donepezil is approved for treatment of dementia of the Alzheimer type and is currently available only in tablet forms in the United States. Objective: To compare steady-state pharmacokinetics of once-weekly 10-mg/d and 5-mg/d Corplex™ donepezil transdermal delivery systems (TDS) with once-daily 10-mg oral donepezil. Methods: Open-label, randomized, crossover study (NCT04617782) enrolled healthy participants aged 18–55 years. All participants received 5-mg/d donepezil TDS during the 5-week Period 1, followed by 10-mg/d TDS or 10-mg/d oral donepezil in the 5-week Period 2; treatments were switched in Period 3. Bioequivalence was assessed at steady state on Week 5. Results: All 60 enrolled participants received 5-mg/d TDS, 55 received 10-mg/d TDS, and 56 received oral donepezil. Adjusted geometric mean ratio (% [90% CI]) for maximum plasma concentration and area under the plasma concentration versus time curve (0–168 h) were 88.7 (81.7–96.2) and 108.6 (100.5–117.4) for 10-mg/d and 86.1 (79.8–92.9) and 105.3 (97.6–113.6) for dose-normalized 5-mg/d TDS and were generally within the 80% –125% range for establishing bioequivalence with oral donepezil. Skin adhesion was similar for both TDSs (>80% of patches remaining ≥75% adhered throughout the wear period). Overall incidence of adverse events (AEs) was similar across treatments. Compared with 10-mg/d TDS, oral donepezil was associated with higher incidence of gastrointestinal and nervous system AEs (14.5% versus 53.6% and 14.5% versus 30.4%, respectively). Conclusion: Donepezil TDSs are bioequivalent to oral donepezil at steady state and have a safety profile that supports their use in treating dementia of the Alzheimer type.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-220530

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design. QD, once daily; QW, once weekly; TDS, transdermal delivery system.
Fig. 1 Study design. QD, once daily; QW, once weekly; TDS, transdermal delivery system.CC BY-NC · PubMed Central
Fig. 2 Participant disposition and analyses populations. *These participants were randomized to receive 10 mg/d donepezil TDS followed by oral donepezil. †Two participants discontinued from the trial in Period 3 because of noncompliance with the protocol or in-house rules. d, day; TDS, transdermal delivery system.
Fig. 2 Participant disposition and analyses populations. *These participants were randomized to receive 10 mg/d donepezil TDS followed by oral donepezil. †Two participants discontinued from the trial in Period 3 because of noncompliance with the protocol or in-house rules. d, day; TDS, transdermal delivery system.CC BY-NC · PubMed Central
Fig. 3 Mean steady-state (Week 5) plasma concentration-time curves for 5 mg/d donepezil TDS, 10 mg/d donepezil TDS, and 10 mg/d oral donepezil. Donepezil TDS was applied weekly for 5 weeks; oral donepezil was administered daily for 5 weeks. The replicated steady-state pharmacokinetic profile for oral donepezil on Days 1–6 is shown as a dashed line to represent that they are replicated from Day 7 (144–168 h). TDS, transdermal delivery system.
Fig. 3 Mean steady-state (Week 5) plasma concentration-time curves for 5 mg/d donepezil TDS, 10 mg/d donepezil TDS, and 10 mg/d oral donepezil. Donepezil TDS was applied weekly for 5 weeks; oral donepezil was administered daily for 5 weeks. The replicated steady-state pharmacokinetic profile for oral donepezil on Days 1–6 is shown as a dashed line to represent that they are replicated from Day 7 (144–168 h). TDS, transdermal delivery system.CC BY-NC · PubMed Central
Fig. 4 Donepezil exposure for (A) 10 mg/d donepezil TDS and (B) 5 mg/d donepezil TDS (dose normalized) versus oral donepezil. Bars are the 90% CIs. AUC0168,ss, area under the curve at steady state; CI, confidence interval; Cmax,ss, maximum concentration at steady state; LSM, least-squares mean; TDS, transdermal delivery system.
Fig. 4 Donepezil exposure for (A) 10 mg/d donepezil TDS and (B) 5 mg/d donepezil TDS (dose normalized) versus oral donepezil. Bars are the 90% CIs. AUC0168,ss, area under the curve at steady state; CI, confidence interval; Cmax,ss, maximum concentration at steady state; LSM, least-squares mean; TDS, transdermal delivery system.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 24

Metadata

Authors
Tariot, P. N., Braeckman, R., & Oh, C.
Affiliations
  • Banner Alzheimer’s Institute (US)
  • KemPharm (United States) (US)
  • Corium Inc., Grand Rapids, MI, USA
Corresponding author
Oh, Charles
Venue
Journal of Alzheimer's Disease
Published
2022-10-25
Volume
90
Issue
1
Pages
161-172
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W4296326377
Cited by
24
References
17
Citations by year
2026: 9 · 2025: 7 · 2024: 4 · 2023: 4
FWCI
2.24
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
donepezil, transdermal drug delivery
MeSH terms
Donepezil, Adolescent, Adult, Alzheimer Disease, Humans, Middle Aged, Cross-Over Studies, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. https://app.cochat.ai/papers/10.3233/jad-220530
The paper
Tariot, P. N., Braeckman, R., & Oh, C. (2022). Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-220530

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.